Insider Selling: Definium Therapeutics (NASDAQ:DFTX) CFO Sells $123,496.89 in Stock

Definium Therapeutics, Inc. (NASDAQ:DFTX) CFO Brandi Roberts sold 3,377 shares of Definium Therapeutics stock in a transaction on Friday, September 25th. The shares were sold at an average price of $36.57, for a total value of $123,496.89. Following the completion of the transaction, the chief financial officer directly owned 394,528 shares of the company’s stock, valued at $14,427,888.96. This represents a 0.85% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Definium Therapeutics Stock Performance

NASDAQ:DFTX opened at $37.60 on Friday. The company has a market cap of $5.05 billion, a price-to-earnings ratio of -10.96 and a beta of 2.19. Definium Therapeutics, Inc. has a fifty-two week low of $10.46 and a fifty-two week high of $49.70. The company has a debt-to-equity ratio of 0.04, a quick ratio of 6.95 and a current ratio of 6.95. The stock has a fifty day moving average price of $41.15 and a 200-day moving average price of $32.34.

Definium Therapeutics (NASDAQ:DFTX) last issued its quarterly earnings results on Thursday, August 6th. The company reported ($1.44) EPS for the quarter, missing analysts’ consensus estimates of ($0.55) by ($0.89). As a group, equities analysts anticipate that Definium Therapeutics, Inc. will post -3.02 EPS for the current fiscal year.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently made changes to their positions in the stock. Sequoia Financial Advisors LLC acquired a new stake in shares of Definium Therapeutics in the 2nd quarter valued at approximately $812,000. WINTON GROUP Ltd acquired a new position in Definium Therapeutics during the 2nd quarter worth approximately $240,000. Engineers Gate Manager LP bought a new position in Definium Therapeutics in the 2nd quarter valued at approximately $481,000. Integrated Wealth Concepts LLC bought a new position in Definium Therapeutics in the 2nd quarter valued at approximately $159,000. Finally, NewEdge Advisors LLC acquired a new stake in Definium Therapeutics in the second quarter valued at approximately $222,000. Institutional investors own 27.91% of the company’s stock.

Analysts Set New Price Targets

Several equities analysts have commented on the stock. Wells Fargo & Company raised their target price on shares of Definium Therapeutics from $68.00 to $72.00 and gave the company an “overweight” rating in a report on Thursday, August 13th. Citigroup reiterated a “buy” rating on shares of Definium Therapeutics in a research report on Monday, June 22nd. Leerink Partners set a $52.00 price objective on shares of Definium Therapeutics and gave the company an “outperform” rating in a research report on Monday, June 22nd. Oppenheimer restated an “outperform” rating and set a $75.00 target price on shares of Definium Therapeutics in a research note on Monday, September 14th. Finally, Stifel Nicolaus raised their target price on Definium Therapeutics from $30.00 to $60.00 and gave the company a “buy” rating in a report on Wednesday, July 8th. Two investment analysts have rated the stock with a Strong Buy rating, eighteen have assigned a Buy rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat, the stock currently has a consensus rating of “Buy” and a consensus price target of $64.88.

Definium Therapeutics Company Profile

Definium Therapeutics, Inc, a clinical stage biopharmaceutical company, develops novel products to treat brain health disorders. The company’s lead product candidates include MM120, which is in phase 3 for the treatment of generalized anxiety disorder and attention deficit hyperactivity disorder; and DT402, a R-enantiomer of 3,4-methylenedioxymethamphetamine, which is in phase 2a clinical trials for the treatment of core symptoms of autism spectrum disorder. The company was formerly known as Mind Medicine (MindMed) Inc and changed its name to Definium Therapeutics, Inc in January 2026.